Marketing

GSK licenses investigational liver disease treatment linerixibat to Alfasigma for global development and commercialisation

(IN BRIEF) GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise…

3 weeks ago